Profile data is unavailable for this security.
About the company
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonium and hydroxyl ions. By doing so at the site of cancerous tissues in the body, DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. Its pipeline includes L-DOS47 monotherapy NSCLC, L-DOS47 combo PEM/CARBO NSCLC, L-DOS47 DOXO combo Pancreas, and L-DOS47 combo Immune Checkpoints.
- Revenue in CAD (TTM)0.00
- Net income in CAD-6.14m
- Incorporated2008
- Employees9.00
- LocationHelix BioPharma CorpBay Adelaide Centre - North Tower 40Temperance Street, Suite 2700 TorontoTORONTO M5H 0B4CanadaCAN
- Phone+1 (604) 684-2181
- Fax+1 (905) 841-2244
- Websitehttps://www.helixbiopharma.com/